Background: Drug monitoring is a useful tool for obtaining detailed information about the
disposition of a drug in an individual patient during chemotherapy. According to the …

Aim: Capecitabine, a 5-fluorouracil prodrug, has been integrated into the management of
multiple cancer types. In order to obtain information about plasma levels of capecitabine in …

Capecitabine is a prodrug of 5-fluorouracil, employed as a monotherapy or combination
chemotherapy agent for treatment of colorectal cancer. Combination therapy of capecitabine …

Capecitabine is a prodrug of 5‐flurouracil, employed as a broad spectrum chemotherapeutic
agent. It is also used as monotherapy or a combination chemotherapy agent for the …

The aim of the present study was to assess the pharmacokinetics (PK) of metronomic
capecitabine and its metabolites in a population of refractory metastatic colorectal cancer …

Aims To assess the relationship between systemic exposure to capecitabine metabolites
and parameters of efficacy and safety in patients with advanced or metastatic colorectal …

706 Background: Capecitabin is a prodrug converted into 5-FU via two phases of
metabolites, 5'-DFCR and 5'-DFUR. In order to elucidate intra-individual variation of …

Aim: Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely
used in the management of colorectal cancer. This study was designed to investigate …

Introduction In this study, we assessed the pharmacokinetics (PK), bioequivalence, and
safety of 150 mg capecitabine compared to the branded reference formulation in colorectal …

Purpose The objective of this study was to compare the pharmacokinetics and safety of two
tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in …